260 related articles for article (PubMed ID: 24889558)
1. Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNα-2a and ribavirin in Iranian patients with chronic hepatitis C.
Sadeghi F; Bokharaei-Salim F; Salehi-Vaziri M; Monavari SH; Alavian SM; Salimi S; Vahabpour R; Keyvani H
J Med Virol; 2014 Sep; 86(9):1499-506. PubMed ID: 24889558
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
Di Bisceglie AM; Janczweska-Kazek E; Habersetzer F; Mazur W; Stanciu C; Carreno V; Tanasescu C; Flisiak R; Romero-Gomez M; Fich A; Bataille V; Toh ML; Hennequi M; Zerr P; Honnet G; Inchauspé G; Agathon D; Limacher JM; Wedemeyer H
Gastroenterology; 2014 Jul; 147(1):119-131.e3. PubMed ID: 24657484
[TBL] [Abstract][Full Text] [Related]
3. Expression of TRIM22 mRNA in chronic hepatitis C patients treated with direct-acting antiviral drugs.
Naveed M; Ali A; Sheikh N; Rafique S; Idrees M
APMIS; 2020 Apr; 128(4):326-334. PubMed ID: 31863490
[TBL] [Abstract][Full Text] [Related]
4. [Dynamic changes in PD-1, TLR3, and TLR4 surface expression on peripheral blood mononuclear cells in chronic hepatitis C patients undergoing peg-IFNalpha-2a plus ribavirin combination therapy].
Zhang M; Jiang YF; Xiao XQ; Liu SF; Peng ML; Liu D; Gong GZ
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):196-201. PubMed ID: 23967741
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of TRIM5 and TRIM22 polymorphisms on treatment responses in Iranian patients with chronic hepatitis C virus infection.
Mobasheri S; Irani N; Sepahi AA; Sakhaee F; Jamnani FR; Vaziri F; Siadat SD; Fateh A
Gene; 2018 Nov; 676():95-100. PubMed ID: 30017737
[TBL] [Abstract][Full Text] [Related]
6. [Short-term curative effect of ribavirin combination therapy with pegylated interferon alfa-2a vs. interferon alfa-2a in patients with chronic hepatitis C].
Wang M; Zheng W; Zhang H; Li Z; Jiang D; Liu Y; Zhou R; Li XG; Zhang Y; Zhang Z; Wu S; Zhang Y; Li J
Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):255-9. PubMed ID: 25173222
[TBL] [Abstract][Full Text] [Related]
7. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
9. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
[TBL] [Abstract][Full Text] [Related]
10. Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy.
Ueda T; Tsuchiya K; Hashimoto S; Inoue T; Enomoto N; Inao M; Tanaka A; Kaito M; Imazeki F; Nishiguchi S; Mochida S; Yokosuka O; Yatsuhashi H; Izumi N; Kudo M;
Dig Dis; 2012; 30(6):554-60. PubMed ID: 23258094
[TBL] [Abstract][Full Text] [Related]
11. IFN-stimulated gene expression is a useful potential molecular marker of response to antiviral treatment with Peg-IFNα 2b and ribavirin in patients with hepatitis C virus genotype 1.
Sixtos-Alonso MS; Sánchez-Muñoz F; Sánchez-Ávila JF; Martínez RA; Domínguez López A; Vargas Vorácková F; Uribe M
Arch Med Res; 2011 Jan; 42(1):28-33. PubMed ID: 21376259
[TBL] [Abstract][Full Text] [Related]
12. Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection.
Oh IS; Won JW; Kim HJ; Lee HW
Korean J Intern Med; 2017 Nov; 32(6):1010-1017. PubMed ID: 28797159
[TBL] [Abstract][Full Text] [Related]
13. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection.
Brost S; Zimmermann A; Koschny R; Sykora J; Stremmel W; Schirmacher P; Walczak H; Ganten TM
Pathol Res Pract; 2014 Feb; 210(2):83-91. PubMed ID: 24268735
[TBL] [Abstract][Full Text] [Related]
15. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
He LL; Chen Z; Chen Y; Xu H; Tang H; Lei BJ; Lei XZ
Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):34-7. PubMed ID: 21272456
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of combination therapy with pegylated-interferon alfa-2a plus ribavirin in autoantibody-positive chronic hepatitis C patients].
Li YX; Yang YJ; Yang M; Chen LY; Lu JJ; Ma YJ; Liu K; Lei XZ; Tang H
Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):345-7. PubMed ID: 24025134
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.
Villa E; Cammà C; Di Leo A; Karampatou A; Enea M; Gitto S; Bernabucci V; Losi L; De Maria N; Lei B; Ferrari A; Vukotic R; Vignoli P; Rendina M; Francavilla A
J Viral Hepat; 2012 Sep; 19(9):640-9. PubMed ID: 22863268
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
20. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.
Rotman Y; Noureddin M; Feld JJ; Guedj J; Witthaus M; Han H; Park YJ; Park SH; Heller T; Ghany MG; Doo E; Koh C; Abdalla A; Gara N; Sarkar S; Thomas E; Ahlenstiel G; Edlich B; Titerence R; Hogdal L; Rehermann B; Dahari H; Perelson AS; Hoofnagle JH; Liang TJ
Gut; 2014 Jan; 63(1):161-9. PubMed ID: 23396509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
